Gene therapy and market access: the pharmaphorum podcast

from pharmaphorum Podcast · host pharmaphorum

For episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio in the UK. The Cambridge, Massachusetts-based company has gone from being a gene therapy start-up to having three potential blockbusters on its books, with a CAR-T cancer medicine and potential treatments for a type of sickle-cell disease and a rare and deadly genetic brain disease.

Episode metadata supplied by the publisher feed · Published May 31, 2019

Embed this episode

Attribution link and audio player

NOW PLAYING

Gene therapy and market access: the pharmaphorum podcast

0:00 20:07

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of pharmaphorum Podcast?

This episode is 20 minutes long.

When was this pharmaphorum Podcast episode published?

This episode was published on May 31, 2019.

Can I download this pharmaphorum Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!